Healthcare
Laboratorios Farmaceuticos Rovi, S.A.(LABFF)
Live Price
Offline$90.61
+0.00% today
1Y Change
+0.00%
Window
Jun 26, 2025 β Jun 23, 2026
- Market Cap
- $4.06B
- Revenue Growth
- -2.7%
- EPS Growth
- +3.0%
- Dividend Yield
- 1.2%
Coverage: 249 bars Β· Jun 26, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) is a Healthcare stock with a market cap of $4.06B and listed on OTC. The stock last traded around $90.61 and up 0.0% across the available one-year price window (Jun 26, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of -2.7%, EPS growth of +3.0%, a dividend yield of 1.2%. What stands out right now is revenue -2.7%, EPS +3.0%, free cash flow +57.9% with operating margin 24.5% and ROIC 17.1%. The dividend is present but secondary, with a yield around 1.2%. Valuation sits in the middle of the pack at P/E 28.9 and price/sales 5.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LABFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-2.7% vs +7.6% peer median
Operating Margin
Above sector median
+24.5% vs +19.4% peer median
P/E
Below sector median
28.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -2.7% and EPS is at +3.0%, with operating margin around 24.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | β | +0.0% | +0.0% | +0.0% |
2026 Feb 25, 2026 | β | +0.0% | +0.0% | +0.0% |
2025 Nov 6, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
LABFF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LABFF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LABFF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LABFF and SPY.
Company Overview
Laboratorios Farmaceuticos Rovi, S.A.
Other OTC
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÑn to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
- Leadership
- Juan Lopez-Belmonte Encina
- IPO Date
- Apr 5, 2021
- Employees
- 2.2k
- Street Address
- Calle JosΓ© Isbert, 2
- Mailing
- Madrid, 28223
- Region
- Madrid, ES
- Reporting Currency
- USD
- Investor Line
- 34 91 021 30 00
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 28.9
- EV/EBITDA
- 19.3
- Price/Sales
- 5.5
- Price/Book
- 6.1
Growth
- Revenue
- -2.7%
- EPS
- +3.0%
- Free Cash Flow
- +57.9%
Profitability
- Gross Margin
- 63.8%
- Operating Margin
- 24.5%
- Net Margin
- 18.9%
- ROE
- 23.0%
- ROIC
- 17.1%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 3.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.